格隆汇12月31日丨云康集团(02325.HK)宣布，于2025年12月31日，云康产业的附属公司广州达安与达安 基因订立新物业租赁协议，据此，(i)达安基因同意向集团租赁物业；及(ii)达安基因同意向集团提供水 电等相关服务，均自2026年1月1日起至2028年12月31日止为期三(3)年。 ...

Core Insights - The article highlights the growing focus on future industries in China, as emphasized in the "14th Five-Year Plan," which aims to cultivate and expand emerging industries and future sectors [1] - It discusses the importance of exploring diverse technological routes, typical application scenarios, feasible business models, and market regulatory rules to drive economic growth through sectors like quantum technology, biomanufacturing, hydrogen energy, nuclear fusion, brain-computer interfaces, embodied intelligence, and 6G mobile communication [1] Group 1: Market Trends - The article notes that over 381 concept stocks have seen a decline in shareholder numbers compared to the end of Q3, with more than 40 companies experiencing a decrease, and 27 companies showing a decline exceeding 3% [1] - 福晶科技 (Fujing Technology) has seen a significant drop in shareholder numbers, with a decrease of nearly 26% compared to the end of Q3 [1] Group 2: Investment Opportunities - Among the 27 companies with a shareholder decline over 3%, only 10 companies have recorded a year-to-date increase of less than 19%, indicating potential for price recovery in the future industry sector [1] - The table lists several companies with their respective year-to-date performance and shareholder decline percentages, highlighting potential stocks for future investment, such as 致远新能 (Zhiyuan New Energy) with a 3.59% increase and a 10.40% decline in shareholder numbers [2]

9月22日早盘，体外诊断板块表现活跃，截至上午10：00，其整体上涨3.13%，位居大智慧板块涨幅榜 前列，博晖创新涨停，利德曼也大涨11.76%，硕世生物、达安基因也分别大涨9.17%、9.01%，东方生 物(8.78%)、圣湘生物(8.04%)、明德生物(6.77%)、华大基因(6.39%)、理邦仪器(5.99%)和万泰生物 (6.21%)等个股涨幅也均逾6%。 分析人士表示，体外诊断产业链主要应用场景在医院检验科、独立医学实验室(ICL， IndependentClinicalLaboratory)、体检中心、防疫站、血站等。下游需求端景气度较高，IVD高速增长接 近20%。从终端用户来看，2018年国内IVD产品主要客户公立医院的检查收入达3157亿元、同比增速为 12.48%，重要客户ICL和体检中心行业增速也在20%左右或以上。下游需求旺盛带动上游市场规模的快 速增长，2018年中国IVD行业规模713亿元，同比增长25.6%，远超全球IVD市场6.0%的增速。体外诊断 板块孕育大企业，发光细分景气度佳，具有业绩支撑的龙头股值得关注。(任世碧) ...

证券日报网讯12月23日，达安基因（002030）在互动平台回答投资者提问时表示，公司仅提供每月月末 股东人数，截至2025年11月28日，公司股东总户数约为135000户。 ...

格隆汇12月16日丨达安基因(002030.SZ)在互动平台表示，不涉及违反外商投资相关法律法规的情形。 香港中央结算有限公司作为港交所全资附属的结算机构，经营香港的中央结算及交收系统，其并非实质 持股，而是代表香港及海外投资者持有通过沪港通、深港通投资A股的股份。公司为深股通标的上市公 司，有投资者通过深港通购买公司股票，都会通过"香港中央结算有限公司"账户名称体现。 ...

证券日报网讯12月15日，达安基因（002030）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司股东总户数约为13万5千户。 ...

证券日报网讯12月8日，达安基因（002030）在互动平台回答投资者提问时表示，目前国家积极的化债 措施有助于公司加快应收账款回收，对此公司高度重视，已设立应收账款专项工作小组，多措并举加大 应收账款的回款力度，各项工作有序推进中。公司具体财务数据请关注公司定期报告等相关公告。 ...

Core Insights - The biopharmaceutical sector is one of the fastest-growing areas in the pharmaceutical industry, driven by an aging population and increased public health awareness [1][5] - China's biopharmaceutical market is projected to grow from CNY 312 billion in 2019 to CNY 587.1 billion in 2024, and is expected to reach CNY 675.2 billion by 2025, with a potential to hit CNY 1.149 trillion in the next five years [1][5][6] - Innovation remains the core driver of growth in the biopharmaceutical industry, which is capital-intensive and requires significant R&D investment [1][6] Industry Definition and Classification - Biopharmaceuticals are medical products manufactured using biological methods, aimed at replicating the activity of natural substances [2][4] - They can be categorized into vaccines, blood products, biopharmaceutical drugs, diagnostic reagents, and others, with further subdivisions based on source or mechanism of action [2] Current Industry Status - The global biopharmaceutical market is expected to grow from USD 286.4 billion in 2019 to USD 461.6 billion in 2024, with the original biopharmaceutical market projected to increase from USD 268.9 billion to USD 427.9 billion in the same period [5] - China plays a significant role in the global biopharmaceutical market, with rapid growth driven by favorable policies, increased R&D investment, and advancements in biotechnology [5][6] Industry Development Environment - Policies - The Chinese government has implemented various laws and policies to encourage biopharmaceutical R&D, including the Drug Registration Management Measures and regulations for clinical research and application of biomedical technologies [7] Competitive Landscape - The biopharmaceutical sector is recognized as a "new frontier" in the pharmaceutical industry, with major global players actively entering the market [9] - Key companies in China's biopharmaceutical industry include WuXi AppTec, Hengrui Medicine, ZhiFei Biological, BeiGene, and others, with a competitive landscape characterized by differentiated strategies [9] Future Development Trends - Market demand for biopharmaceuticals is expected to continue growing, supported by policy backing, technological advancements, and increased health awareness [10] - Domestic companies are transitioning from biosimilars to First-in-Class drugs, with examples like Hengrui Medicine's ADC drug showing superior efficacy [10][11] - Personalized medicine based on genetic testing is anticipated to become a trend, with increasing international recognition of Chinese innovative drugs [11]

证券日报网讯12月2日，达安基因（002030）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司股东总户数约为13万5千户。 ...

Core Insights - The avian influenza concept sector experienced a decline of 0.76%, ranking among the top losers in the market, with major stocks like Zhongsheng Pharmaceutical hitting the limit down, while a few stocks like Wens Foodstuff and Weilan Biology saw gains of 1.80% each [1][2] Market Performance - The top-performing concept sectors included Titanium Dioxide with a gain of 4.31%, and Hainan Free Trade Zone with a gain of 3.54%, while the avian influenza sector was among the worst performers [1] - The avian influenza sector saw a net outflow of 784 million yuan, with 18 stocks experiencing net outflows, led by Zhongsheng Pharmaceutical with a net outflow of 684 million yuan [1] Stock Performance - Stocks with significant net outflows included: - Zhongsheng Pharmaceutical: -10.00% with a turnover rate of 18.78% and a net outflow of 683.65 million yuan - Yiling Pharmaceutical: -2.40% with a net outflow of 35.71 million yuan - Lianhuan Pharmaceutical: -1.79% with a net outflow of 25.69 million yuan - Hualan Biological: -6.60% with a net outflow of 18.13 million yuan [1] - Conversely, stocks with net inflows included: - Tiankang Biological: +1.26% with a net inflow of 16.52 million yuan - Shanghai Kaibao: -1.70% with a net inflow of 5.06 million yuan - Jinhai Biological: +0.16% with a net inflow of 3.82 million yuan [2]